Overview

NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission.

Last reviewed: 15 January 2025

Next review: We will review this decision if the company decides to make an evidence submission.

Guidance development process

How we develop NICE technology appraisal guidance

This terminated appraisal partially updates and replaces NICE technology appraisal guidance 697 on andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban.